Search Results - "Backes F"

1132P Utility of circulating tumor DNA (ctDNA) dynamics for evaluating early treatment response in patients with recurrent/metastatic endometrial (rEC) and recurrent/platinum-resistant ovarian cancer (rPROC).

Authors: Cosgrove, C. Backes, F. Scalise, C.B. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS752-S753. 2p.

Application of canola oil operation in a diesel engine with common rail system.

Authors: Li, Q. Backes, F. Wachtmeister, G.

Source: Fuel (0016-2361). Nov2015, Vol. 159, p141-149. 9p.

Subjects: Canola oil, Diesel fuels, Vegetable oils as fuel, Surface tension, Fuel pumps, Combustion chambers

This result is not displayed to guests.
Login for full access.

Robotic trocar site small bowel evisceration after gynecologic cancer surgery.

Authors: Seamon LG Backes F Resnick K et al.

Source: Obstetrics & Gynecology. Aug2008, Vol. 112 Issue 2 part 2, p462-464. 3p.

Etude de quelques transformations des courbes et des surfaces.

Authors: BACKES, F.

Source: Académie Royale des Sciences, de Lettres et des Beaux-Arts de Belgique. Classe des Sciences. Mémoires. Collection in-8o; 1923, Vol. 2 Issue 8, p72p-72p, 1p

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

Authors: Van Gorp, T. Cibula, D. Lv, W. et al.

Source: Annals of Oncology. Nov2024, Vol. 35 Issue 11, p968-980. 13p.

Does IORT at the time of pelvic exenteration impact survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?

Authors: Backes, F. Huffman, L. Tierney, B. et al.

Source: Gynecologic Oncology. Jul2013, Vol. 130 Issue 1, pe108-e108. 1p.

Are postmenopausal women with body mass indices <30 with grade 1 endometrial cancer more likely than their obese counterparts to have advanced or recurrent disease?

Authors: Backes, F. Rath, K. McCann, G. et al.

Source: Gynecologic Oncology. Jul2013, Vol. 130 Issue 1, pe78-e79. 0p.

Complications After Double-Barreled Wet-Ostomy Compared to Separate Urinary and Fecal Diversion During Pelvic Exenteration: Time to Change Back?

Authors: Backes, F. Tierney, B. Eisenhauer, E. et al.

Source: Gynecologic Oncology. May2012, Vol. 125 Issue 2, pS190-S190. 1p.

Endometrial cancer staging in the elderly: Robotic or open?

Authors: Backes, F. Farrell, R. Brudie, L. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS149-S149. 1p.

Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

Authors: Backes, F. Richardson, D. McCann, G. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS94-S94. 1p.

Short- and long-term morbidity and outcomes after robotic surgery for endometrial cancer staging

Authors: Backes, F. Brudie, L. Farrell, M. et al.

Source: Gynecologic Oncology. Mar2011 Supplement 1, Vol. 120, pS41-S41. 1p.

Survival outcomes for women with uterine malignancy undergoing robot-assisted laparoscopic staging procedures

Authors: Brudie, L. Backes, F. Ahmad, S. et al.

Source: Gynecologic Oncology. Mar2011 Supplement 1, Vol. 120, pS95-S95. 1p.

Compliance with recommended genetic counseling for Lynch syndrome: Room for improvement

Authors: Backes, F. Mitchell, E. Hampel, H. et al.

Source: Gynecologic Oncology. Mar2011 Supplement 1, Vol. 120, pS58-S59. 0p.

2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial.

Authors: Yang, Y.A. Mortazavi, A. Presley, C. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1538-S1538. 1p.

1152P Cyclin E1 amplification (CCNE1amp) is associated with race and poor outcomes in endometrial cancer (EC).

Authors: Hacker, K. Thomas, S. Lightfoot, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS761-S761. 1p.

1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer.

Authors: Rimmel, B. Bender, D. Enserro, D. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS742-S742. 1p.

1113P Post hoc survival outcomes based on initial and subsequent treatment in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Authors: Powell, M.A. Roed, H. Gilbert, L. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS740-S740. 1p.

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Authors: Bixel, K. Vetter, M. Davidson, B. et al.

Source: Gynecologic Oncology. Mar2020, Vol. 156 Issue 3, p530-534. 5p.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors: González-Martín, A. Pothuri, B. Vergote, I. et al.

Source: New England Journal of Medicine. 12/19/2019, Vol. 381 Issue 25, p2391-2402. 12p.